46
Participants
Start Date
April 30, 2014
Primary Completion Date
January 31, 2016
Study Completion Date
April 30, 2016
ME-344
"Part 1: ME-344 IV at 10 mg/kg on Days 1, 8, 15, and 22 of each 28-day cycle. Part 2: ME-344 IV at the dose defined in Part 1 on Days 1, 8, 15, and 22 of each 28 day cycle.~Patients will be allowed to continue receiving ME-344 infusions weekly according to the assigned dose level as long as there is clinical benefit to the patient as assessed by the Investigator."
Topotecan
Part 1: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle. Part 2: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle.
Medical University of South Carolina, Charleston
Tennessee Oncology, PLLC, Nashville
Oncology Hematology Care, Cincinnati
Northwestern University, Chicago
University of Oklahoma, Oklahoma City
University of Colorado Cancer Center, Aurora
Pinnacle Oncology Hematology, Scottsdale
University of WA Seattle Cancer Care Alliance, Seattle
The Bays St Mary's Hospital, London
Sarah Cannon Research Instititute UK, London
Lead Sponsor
SCRI Development Innovations, LLC
OTHER
MEI Pharma, Inc.
INDUSTRY